IntegriCell Logo_Color (3)

Our Mission

The IntegriCell™ platform aims to establish a standardized, integrated apheresis collection, cryopreservation, and distribution solution for the global Cell Therapy market.

The IntegriCell™ platform combines 

  • Cryoport’s global leadership in temperature-controlled supply chain solutions and storage

  • Cell Matters' experience and expertise in cryopreservation

  • Leukapheresis collection capabilities via third party strategic partnerships to meet the current and future needs of the market

The goal is to streamline the complex processes necessary to treat an increasing number of patients with today's most advanced cell therapies while ensuring the highest quality and safety standards.

The Value We Offer

  • Access to consistent, reliable and standardized collections

  • Cryopreservation within 24h post collection

  • Standardization of cryopreservation protocols, performed by qualified and trained staff, within a controlled environment

  • Manufacturing slot optimization facilitated through cryopreservation

  • US - EU transatlantic bridge to support global clinical trials and commercial products

IntegriCell Infographic 7APRIL2023

Cryopreservation Services & Process Development

  • Ready to use cryopreservation protocol (RUO and GMP)

  • Technology transfer services of clients’ cryopreservation processes to leverage IntegriCell™ model

  • Process development services of specific cryopreservation processes to meet client needs and constraints

Who We Serve

  • Cell Therapy Developers

  • Pharma and Biotech

  • CDMO and CRO

  • Hospitals and Academic Programs

  • Leukapheresis Providers

Our Current Partners

takeda-CTS-logo-final (1)




File:Syneos Health logo.svg - Wikimedia Commons

About Us

  • In July 2022, Cryoport Systems formally acquired Cell Matters

  •  Cell Matters uniquely combines expertise in cryobiology and cell therapy cryopreservation processes

  •  Headquartered in Liege, Belgium, the company enhances cell therapy productivity by turning cryopreservation into a competitive advantage

  •   The acquisition accelerates Cryoport Systems' development of its Global Supply Chain Network by expanding into cryopreservation to meet
        the growing needs of industry worldwide

  •  Cell Matters provides EU and US sites for cryopreservation, which creates additional opportunities for cell therapy developers looking to
    conduct clinical trials or commercially distribute their therapies in the EU and the US

Learn More

Cryoport® is a trademark of Cryoport, Inc. and used with permission by Cryoport Systems, LLC